Pfizer names Cecile Guegan permanent CFO effective Nov. 1, 2026

Pfizer Inc. (NYSE: PFE) has appointed Cecile Guegan as Chief Financial Officer and Executive Vice President, effective November 1, 2026, according to a company statement. The decision was unanimous among Pfizer's Board of Directors.

Guegan has served as interim CFO since August 16, 2026. In that role, she oversaw the company's financial operations, execution, and strategic planning. Prior to the interim appointment, she led financial operations and reporting for Pfizer's biopharmaceutical business across all therapeutic areas and geographies.

In her new role, Guegan will be responsible for all corporate finance functions, including audit, treasury, investor relations, tax, insurance, operations planning and analysis, corporate controllership, and business finance and analytics.

Pfizer Chairman and CEO Albert Bourla commented on the appointment: "Her more than 25 years of experience paired with her strategic vision will provide the financial rigor and focus this next chapter demands as we aim for meaningful growth."

Guegan stated: "My focus remains on executing a disciplined approach to capital allocation while making targeted investments today to drive revenue growth later in the decade and beyond."

Guegan holds a master's degree in Management with a concentration in Audit and Finance from the Graduate School of Management of Brest, France, and a bachelor's degree in Accounting.

You May Also Be Interested In

• Prenetics names Brian J. Rosin as CFO, effective Dec. 31
• Organigram agrees to acquire Aurora Cannabis for C$561M
• Trump Media and TAE Technologies file amended S-4 for merger